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Purpose: To better understand the pathophysiological mechanisms underlying neuromyelitis optica (NMO), we developed
a proteomics platform for biomarker discovery in the cerebrospinal fluid (CSF) of patients with NMO.
Methods: Two-dimensional electrophoresis (2-DE) and matrix-assisted laser desorption ionization time of flight mass
spectrometry (MALDI-TOF MS) were used to compare the CSF proteome of NMO patients with that of controls. A
subsequent ELISA and western blot analysis were performed to verify the results of the proteomic analysis. Pathway
Studio 5.0 software was used to determine possible functional interactions among these differentially expressed proteins.
Results: Using 2-DE and MALDI-TOF MS, we identified 11 differentially expressed proteins and two isoforms of these
same proteins. The expression of four proteins was enhanced, whereas the expression of seven proteins was reduced in
the NMO group in comparison to the control group. These differences in protein expression were confirmed by performing
ELISA and western blot analyses (p<0.01). Protein network analyses revealed biologic interactions and cross-talks among
these differentially expressed proteins.
Conclusions: Because of their unique expression profile in NMO CSFs, these proteins are candidate biomarkers for NMO.
Thus, our findings may have important implications for both the diagnosis of NMO and the further understanding of its
pathogenesis.
Neuromyelitis  optica  (NMO),  also  termed  Devic's
syndrome,  is  an  idiopathic  inflammatory  demyelinating
disease of the central nervous system (CNS) predominantly
affecting optic nerves and the spinal cord [1]. It is a disabling
and,  occasionally,  life-threatening  disease.  Patients  with
NMO can experience relapses of optic neuritis or myelitis that
occur in intervals of months or years. NMO is considered to
be a severe monophasic syndrome characterized by bilateral
optic neuritis (ON) and myelitis occurring in rapid succession.
Furthermore, the prognosis for patients with NMO is often
poor; within five years of disease onset, more than half of
patients will develop severe bilateral visual impairment and
even visual loss in at least one eye and /or inability to ambulate
without assistance within 5 years of disease onset [2-4]. Serum
NMO-immunoglobulin G (IgG) has been investigated, and its
presence is highly specific for NMO [5,6]. However, NMO-
IgG is not detectable in all patients. Therefore, the diagnosis
of NMO is generally based on the combination of clinical,
neuroimaging, laboratory, and pathological findings [7,8]. It
is thus crucial to develop diagnostic tools for NMO. Abnormal
cerebrospinal  fluid  (CSF)  findings  are  one  of  the
characteristics  of  NMO  and  may  provide  important
information  for  deciphering  mechanisms  of  NMO
pathogenesis. It is well accepted that CSF proteomics is a
powerful technique for monitoring protein expression in the
CSF [9]. Moreover, it can provide valuable information about
the CNS disease in general [10,11]. In this study, we examined
the CSF proteome profile of NMO by means of proteomic
analysis  with  two-dimensional  electrophoresis  (2-DE),
followed by matrix-assisted laser desorption ionization time
of flight mass spectrometry (MALDI-TOF MS) and database
searching. We confirmed our findings with ELISA, western
blot analyses, and the establishment of the protein network.
Understanding the expression and function of these disease-
related proteins may enable us to identify them as candidate
biomarkers to aid in the diagnosis of NMO and, perhaps, in
its treatment and prognosis.
METHODS
CSF  samples:  We  collected  CSF  samples  from  34  NMO
patients and 39 controls from Qilu Hospital of Shandong
University, Jinan, China. CSF samples collected from nine
NMO patients (six females and three males; age: 38.1±4.8
years old) and nine controls (five females and four males; age:
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Shanghai 200032, China36.5±6.4 years old) were used to perform 2-DE. CSF samples
collected from 25 NMO patients (16 females and nine males;
age: 35.4±4.2 years old) and 30 controls (15 females and 15
males; age: 38.6±6.5 years old) were used for ELISA. CSF
samples from 15 NMO patients (10 females and five males;
age: 37.5±5.3 years old) and 15 controls (eight females and
seven  males;  age:  35.2±4.6  years  old)  from  the  ELISA
analysis were selected at random for western blot analysis.
Patients  with  NMO  enrolled  in  this  study  received  their
diagnosis based on the criteria of Wingerchuck et al. [12]. The
criteria of the NMO: Patients with a monophasic or relapsing
course of NMO; the cells (polymorphonuclear) >50 /mm3 in
CSF of NMO patients; the lesions extend over three or more
vertebral segments on spinal cord MRI. We collected CSF
from NMO patients whose clinical signs persisted for more
than five days. The clinical signs of NMO patients includes
the  abnormal  signs  of  the  CSF,  the  MRI  and  the  other
abnormal signs in the nervous system. Examination of the
CSF was performed when clinical symptoms were apparent
on  average  for  5  days.  CSF  from  NMO  patients  showed
average cell densities of 52.5±4.3/mm3 and 2–5 oligoclonal
bands  (OGB).  Whereas  in  control  samples,  MRI  showed
normal vertebral columns. CSF cell counts were 5.0±1.8/mm3
and OGBs were not detectable in the CSF. Spinal cord MRI
showed  hyperintensive  signal  (HS)  greater  than  three
vertebral segments (HS>3 in T2-weighted MRI). The MRIs
were performed for the whole patients (NMO patients and the
controls). Whereas in control samples CSF cell counts were
5.0±1.8/mm3 and OGBs were not detectable in the CSF. MRI
showed normal vertebral columns. While first-line therapy for
acute attacks of NMO is intravenous corticosteroids, CSF
samples  were  collected  from  patients  before  initiating
corticosteroid or other immunosuppressive therapy to avoid
affecting  CSF  results.  Among  control  patients  (n=6  with
tension-type headache, n=1 each with drug-induced delirium,
normal pressure hydrocephalus, and trigeminal neuralgia), the
diagnosis was defined according to individual disease criteria.
The  CSF  was  analyzed  to  rule  out  encephalitis  and
subarachnoid  hemorrhage,  and  routine  work-up  revealed
normal clinical and imaging results. The clinical features of
the study participants are summarized in Table 1.
This  study  was  approved  by  the  Human  Ethics
Committee of Shandong Province, China. Written informed
consent was obtained from each patient. All CSF samples used
in this study were obtained from patients undergoing a lumbar
puncture in the L4–L5 vertebral interspace. Each patient had
2 mL of CSF removed. CSF samples were centrifuged at
1,000×  g  (4  °C)  for  10  min  to  eliminate  cells  and  other
insoluble material. The samples were then stored at −80 °C
for further study.
2-DE:  To  display  total  protein  content  in  the  CSF,  high-
abundance  proteins,  such  as  IgG  and  albumin,  were  not
depleted. Initially, 500 μl CSF was mixed with 2,000 μl of ice-
cold acetone and stored overnight at −20 °C to remove salt
from each sample [13]. After centrifugation at 16,000× g at
4 °C for 30 min, the protein pellet was washed twice with 90%
acetone  and  air-dried.  Then,  precipitated  proteins  were
solubilized in lysis buffer containing 7 M urea, 2 M thiourea,
4%  cholamidopropyl  dimethylamino  propanesulfonate
(CHAPS), 65 mM dithiothreitol (DTT), and 2% immobilized
pH gradient (IPG), pH 3–10 nonlinear (NL; GE Healthcare,
Piscataway, NJ) for 30 min at room temperature. A Bradford
assay was performed to determine the protein concentration
[14]. The IPGphor system (GE Healthcare) with 18 cm IPG
strip was used for isoelectric focusing electrophoresis (IEF)
at pH 3–10 NL. Next, 100 μg of the protein for analytical runs
or 1,000 μg of the protein for preparative runs were mixed
with  the  rehydration  solution  containing  8  M  urea,  2%
CHAPS, 18 mM DTT, and 0.5% IPG buffer to obtain a total
volume of 340 μl per strip. After rehydration for 12 h at 20 °C,
IEF was performed as follows: 200 V for 1 h, 500 V for 1 h,
1,000 V for 1 h, gradient to 8,000 V over 2 h, 8,000 V for
60,000 V hours. Vertical SDS–PAGE (12.5% T, 2.75% C)
was run in a Protean II xi two-dimensional cell (Bio-Rad,
Hercules,  CA).  The  preparative  gels  were  stained  with
Coomassie brilliant blue G-250, and the analytical gels were
stained with silver according to manufacturer’s instructions.
Image analysis: Silver-stained gels were scanned using an
UMAX PowerLook 2100XL Image Scanner (GE Healthcare)
with standard conditions for all gels. Intensity calibration was
performed  using  an  intensity  step  wedge  (detection
parameters: Smooth 4; Min Area 10; Saliency 1.5). Image
spots were initially detected, matched, and manually edited
with  the  ImageMaster™  2D  Platinum  5.0  software  (GE
Healthcare).  Quantification  was  given  as  a  spot  volume
percentage (vol %), with each single spot volume normalized
TABLE 1. CLINICAL FEATURES AND LABORATORY VALUES OF NMO PATIENTS AND CONTROLS.
Number 
(female/male)
Age
(years)
CSF cells
(/mm3)
OGBsa
(bands)
Disease duration
(days)
NMO 9 (6/3) 38.1±4.8 52.5±4.3 2–5 HSb>3 vertebral
segments
5 (3–7)
Controls 9 (5/4) 36.5±6.4 5.0±1.8 0 – 4 (2–6)
Abbreviations:  aOGBs represents oligoclonal band,  bHS represents hyperintensive signal in T2-weighted MRI.
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Diagnosis Spinal cord MRIwith respect to the total spot volume of the 2-DE gel. The
differences in spot volume was used as a measure of changes
in protein expression levels between the NMO and control
groups,  and  were  ascertained  statistically  by  the  Mann–
Whitney  U-test,  where  a  p  value  <0.05  was  considered
significant. The Mr and pI of each protein spot were calibrated
against known protein markers.
MALDI-TOF  MS  and  database  searching:  Differentially
expressed  protein  spots  were  manually  excised  from  the
preparative gels. Excised gel pieces were destained in 50 mM
NH4HCO3/50% acetonitrile (ACN) to remove all traces of
Coomassie brilliant blue. Destained gel pieces were dried by
vacuum centrifugation and resuspended in 50 mM NH4HCO3
solution containing 10 ng/μl trypsin. Trypsin digestion was
performed at 37 °C for 24 h. The resulting peptide mixtures
were  extracted  with  200  μl  of  60%  ACN  and  0.1%
trifluoroacetic acid (TFA) for 20 min with sonication, and the
supernatant  was  removed.  The  peptide  mixtures  were
deposited on the MALDI probe (the matrix were 2 mg/ml α-
cyano4-hydroxy  cinnamic  acid  in  50%  acetonitrile,  0.1%
trifluoroacetic acid containing 10 mM ammonium phosphate)
and  analyzed  on  a  MALDI-TOF  4700  (ABI  Corp,
Framingham,  MA).  The  MALDI/TOF  mass  spectra  were
recorded in positive ion reflection mode. The accelerating
potential was 20 kV, and the trypsin autodigestion peaks were
used as external calibration. When we analyzed the spectrum
peaks, the trypsin autodigestion peaks were filtered. Peptide
mass fingerprints (PMF) were obtained after processeing by
Data  Explorer  software  softwareVersion  4.0.0.0  (GE
Healthcare,  Piscataway,  NJ).  The  peptide  mass  data  were
searched against Swiss-Prot protein database with the Mascot
search engine and with Homo sapiens as the species searched.
ELISA analysis of haptoglobin: CSF samples from 25 NMO
patients (35.4±4.2 years of age) and 30 controls (38.6±6.5
years of age) were used for the ELISA test. The samples for
ELISA analysis were selected from the 34 NMO patients and
39 controls at random. An ELISA kit for human haptoglobin
(HP; Gentaur, Guangzhou, China) was used, and the assays
were run according to manufacturer’s directions. The data
were acquired on a model 680 microplate reader (Bio-Rad)
with the absorbance wavelength set at 450 nm.
Western blot analysis: Semiquantitation of vitamin D-binding
protein (DBP) was conducted by performing western blot
analysis. CSF samples from 15 NMO (37.5±5.3 years of age)
patients and 15 controls (35.2±4.6 years of age) were used for
this study. Each CSF sample was loaded twice onto the PAGE
gel. Briefly, 8 μg of CSF protein was mixed with 4× loading
buffer   containing   0.5 M  Tris-HCl   (pH 6.8),   8%  SDS, 
0.4%  Bromophenol  Blue,  40%  glycerin  and  5%  β-
Mercaptoethanol. The mixture was boiled for 10 min. 1-DE
separation was performed on a 10% SDS polyacryamide gel,
and 8 μg of CSF protein were loaded per lane with loading
buffer. Next, 5 μl of Easy See Western Marker (TransGen
Biotech Co., Ltd, Beijing, China) was loaded onto the first
lane. Proteins were blotted onto the polyvinylidene difluoride
(PVDF) membrane [15]. When the transfer electrophoresis
was completed, the gel was stained with Coomassie Blue
R250  to  confirm  whether  the  proteins  had  transferred
completely  from  the  gel  to  the  PVDF  membrane.  Mouse
monoclonal anti-vitamin D binding protein (DBP; HYB 249–
01; Abcam, Cambridge, MA) was used to probe DBP, and a
peroxidase-conjugated  goat  anti-mouse  IgG  (ZSGB-Bio,
Guangzhou,  China)  was  used  for  detection.  The  primary
antibody was HYB 249–01 mouse monoclonal anti-(human)
vitamin D binding protein. The color reaction was developed
using  the  Enhanced  Chemiluminescence  Plus  System
(Amersham Biosciences, Piscataway, NJ). Protein bands were
digitally scanned, and the densities of each individual band
were analyzed using Image Quant TL software version 2005
(Amersham Biosciences).
Protein  network  analyses  with  Pathway  Studio  5.0:  To
construct a protein interaction map, we used the Pathway
Studio 5.0 software (Ariadne Genomics, Rockville, MD). It
is able to dynamically create and draw protein interaction
networks and pathways. Each node represents either a protein
entity or a control mechanism of the interaction. It contains
pathway components, protein–protein interactions, proteins
and  their  cellular  processes,  small  molecules,  functional
classes,  and  treatments.  In  addition,  it  has  several  path
analyses and databases. In this study, we selected the shortest
path analysis and the ResNet Databases.
Data  analysis:  Results  were  expressed  as  mean±standard
deviation  (SD).  Differences  in  protein  spots  (volume  %)
between the control group and the NMO group were subjected
to the Mann–Whitney U-test. The Student t-test was applied
to data collected by ELISA and western blot analysis. A p
value < 0.05 was considered significant.
RESULTS
2-DE patterns and identification of differentially expressed
proteins in the NMO CSF: CSF proteins taken from both the
experimental (n=9) and control groups (n=9) were separated
by 2-DE. Two representative silver stained 2-DE gels, which
corresponded to proteomic profiles of the NMO group or the
control group, respectively, are presented in Figure 1A,B .
With the help of ImageMaster™ 2D Platinum 5.0 software,
we detected 388±27 protein spots in the NMO samples and
405±19 protein spots in the control samples. A total of 42
distinct protein spots were detected in the CSF from the NMO
patients  according  to  ImageMaster™  2D  Platinum  5.0
software analysis. These differentially expressed protein spots
were extracted from Coomassie brilliant blue-stained gels and
analyzed by MALDI-TOF MS. Raw data from the MS were
used to search Swissprot database with the Mascot search
engine  (Appendix  1).  Neurofilament  (NF),  HP,
immunoglobulin  kappa  chain  C  region  (IGKC),
Molecular Vision 2009; 15:1638-1648 <http://www.molvis.org/molvis/v15/a175> © 2009 Molecular Vision
1640immunoglobulin  heavy  chain  gamma  3  (IGHG3)  were
upregulated; whereas alpha-1β-glycoprotein (A1BG), DBP,
fibrinogen gamma chain (FGG), pigment epithelium-derived
factor  (PEDF),  apolipoprotein  A-IV  (ApoA-IV),
apolipoprotein  E  (ApoE),  and  transthyretin  (TTR)  were
downregulated in the NMO group in comparison to the control
group. Spot 1 was identified as A1BG with a summary score
of 96 and a protein coverage of 54.3%. However, the second-
best match of this spot only had a summary score of 22 and a
protein  coverage  of  9.6%.  Figure  2  shows  the  PMF  and
Figure  1.  2-DE  results.  A  representative  two-dimensional
electrophoresis (2-DE) gel images of cerebrospinal fluid proteins of
neuromyelitis optica (NMO; A) and control (B). Numbers indicate
proteins that were expressed differentially in the two groups. Protein
spots 2, 6, 8, 11, and 12 were upregulated, whereas the other spots
were downregulated in the NMO group (A) compared to the control
group (B).
matched peptide fragments (A1-A6) of A1BG. The MW in
kDa, pI, volume%, p-value, and MS results are presented in
Table 2. Some of these protein spots were identified as the
same protein (such as spots 8 and 12) by MALDI-TOF-MS.
Protein degradation and fragmentation of proteins, or post-
translational  modifications,  such  as  phosphorylation,  or
different  isoforms  of  the  same  proteins  may  explain  this
phenomenon.
Verification of HP by ELISA: The HP level in the NMO group
(n=25) was 2.67±0.92 μg/mL. This was higher than that of the
control  group  (n=30),  which  exhibited  a  concentration  of
2.08±0.76 μg/ml (p<0.05). HP levels >2.20 μg/ml consistently
identified  patients  with  NMO  with  92.0%  sensitivity  and
83.3% specificity. The Sensitivity was the percentage of the
NMO patients whose HP levels > 2.20 μg/ml account for the
whole NMO patients. The Specificity was the percentage of
the controls whose HP levels < 2.20 μg/ml account for the
whole controls. The Accuracy rate was the percentage of the
NMO patients whose HP levels > 2.20 μg/ml and the controls
whose  HP  levels  <  2.20  μg/ml  account  for  the  whole
participants.The accuracy rate was 87.3%. Thus, HP ELISA
may become an excellent screening tool for the diagnosis of
NMO.
Verification of DBP by western blot: Samples from 15 NMO
patients  and  15  controls  were  selected  for  western  blot
analysis. The results presented in Figure 3A confirmed DBP
as  a  differentially  expressed  target,  as  seen  in  the  2-DE
experiments.  Semiquantitative  densitometric  evaluation  of
the detected protein bands revealed that DBP levels were
decreased in the NMO group by 34%. The average band
intensity in the NMO group was 77±3.87, while the average
band intensity in the control group was 117±5.45 (p<0.01). A
typical western-blot image is shown in Figure 3B.
Protein network: To determine possible functional cross-talk
among  differentially  expressed  target  proteins,  we  built  a
protein network with Pathway Studio 5.0 software (Figure 4).
With  multiple  interacting  binding  partners,  transthyretin
(TTR) functions as an anchoring factor that pulls together
possible  direct  or  indirect  interactions  among  HP,  ApoE,
ApoA-IV,  FGG,  A1BG,  NF,  and  their  transcriptional
regulators.
DISCUSSION
To our knowledge, this is the first comprehensive proteomic
study profiling differential protein expression in the CSF of
NMO patients. There have been few studies characterizing
serum  proteins  or  CSF  proteins  in  NMO  patients  using
immunological  techniques  or  ELISA  assay  [16-18].  In  a
previous study, 2-DE profiling of phosphotyrosyl proteins in
human CSF identified 500 protein spots [9,10]. In the current
study, we identified 11 proteins and 2 isoforms that were
differentially  expressed  in  the  CSF  of  NMO  patients
compared with the controls. Many of these identified proteins
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based  on  their  biochemical  characteristics  and  functions.
These proteins can be classified based on their pro or anti-
inflammatory functions, binding or transport functions, or as
apolipoproteins,  and  proteins  involved  in  neurologic
disorders.
Figure 3. Western-blot results. A: A typical western blot image
against  vitamin  D-binding  protein  (DBP)  in  CSF  of  15  NMO
patients: 1–3 were from NMO patients and 4–6 were from controls.
B: Densitometric analysis of DBP bands in the two groups. Each
column represents the mean±standard deviation (n=15). The average
density value of the NMO group was 77±3.87, and the average
density value of the control group was 117±5.45 (p<0.01). DBP level
was reduced in NMO by 34% as compared to control samples
Proinflammatory or antiinflammatory proteins: Several
investigators have analyzed the CSF proteome in patients with
neurologic diseases [19-22]. In most of those studies, high-
abundance proteins, such as IgG and albumin, were removed
to  enhance  the  detection  of  low-abundance  proteins.
However, such a treatment also results in the loss of some low-
abundance proteins. In our current study, CSF proteins were
profiled  in  their  entirety  so  our  results  provided  a  more
detailed look at the proteins that are normally present in the
CSF. Hence, we were able to better show the changes in
protein  expression  that  had  occurred  due  to  pathological
conditions of NMO.
Notably, the significant increase in the levels of IGHG3
and  IGKC  in  the  CSF  of  NMO  patients  suggest  that
immunological  mechanisms  are  involved  in  the
pathophysiology of NMO [23]. An intrathecal IgG synthesis
inherent to NMO and a compromised blood-brain barrier are
possible  mechanisms  that  can  lead  to  higher  levels  of
immunoglobulin [24].
HP is an acute phase protein that binds free hemoglobin
and exerts antioxidant properties [25]. HP has been proposed
to  be  involved  in  a  highly  interactive  ensemble  of
lymphocytes,  neutrophils,  and  monocytes  participating  in
inflammatory  processes,  and  it  has  been  observed  in
conditions of extensive tissue damage and necrosis [26,27].
In this study, we found a high level of HP in the CSF of patients
with  NMO.  Subsequent  ELISA  confirmed  this  finding.
Moreover, there were reports showing elevated HP levels in
the  CSF  of  patients  with  Guillain-Barré  syndrome,  a
peripheral neuropathy that causes acute neuromuscular failure
[19,20]. Thus, recognizing and monitoring changes in HP may
reveal useful information regarding the disease process and
yield  predictors  for  various  disease  parameters  in  NMO.
Further follow-up studies on HP in the CSF of NMO patients
are warranted.
Figure  2.  Peptide  mass  fingerprint
spectrum of alpha-1β-glycoprotein. The
x-axis  represents  the  mass-to-charge
ratio (m/z), and the y-axis represents the
relative  abundance.  A1-A6  show  the
identified  peptide  fragments  (A1:
CLAPLEGAR;  A2:  LETPDFQLFK;
A3:  HQFLLTGDTQGR;  A4:
CEGPIPDVTFELLR;  A5:
LELHVDGPPPRPQLR;  A6:
VTLTCVAPLSGVDFQLR).
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1643Alpha-1-B glycoprotein (A1BG) is a plasma protein of
unknown function. Conservation at the sequence level with
immuoglobulins and other members of the immunoglobulin
supergene family suggests its possible function in the immune
system and in cell adhesion [28]. A1BG physically interacts
with BCL2L1 and its activities may be modulated by a signal
transducer and activator of transcription 3 (STAT3) through
BCL2L1 (Figure 4). It had been reported that STAT3 might
regulate the transcription of anti-apoptotic proteins such as
BCL-XL that control cell growth and survival [29,30]. Thus,
A1BG and BCL2L1 may play a role in the pathogenesis of
NMO and may become potential therapeutic targets.
Fibrinogen gamma (FGG) is one of the target genes of
STAT3, as STAT3 is reported to control the transcription of
the  FGG  gene  [31].  FGG  is  a  plasma  glycoprotein  with
functions  in  wound  healing  and  anti-inflammation  [32].
Tissue injury in the CNS has been correlated with a post-
traumatic  local  increase  in  fibrinolysis  as  well  as  to  an
inflammatory response [33]. Together, these proteins directly
or indirectly participate in the inflammatory state of NMO,
which may offer new opportunities for biomarker discovery
and the study of the pathogenesis of NMO.
Binding or transport protein: DBP, also known as group-
specific  component  globulin  (Gc-globulin),  is  synthesized
predominantly by hepatic parenchymal cells [34]. DBP is a
Figure  4.  Protein  network  of  the
identified proteins constructed with the
PathwayStudio 5.0 software. Each node
represents either a protein entity or a
control  mechanism  of  the  interaction.
The legend of the interaction network is
summarized under the figure. Numbers
show the identified proteins: alpha-1β-
glycoprotein  (A1BG),  neurofilament
(NF), vitamin D-binding protein (DBP),
fibrinogen  gamma  chain  (FGG),
pigment  epithelium-derived  factor
(PEDF), immunoglobulin heavy chain
gamma 3 (IGHG3), apolipoprotein A-
IV  (ApoA-IV),  haptoglobin  (HP),
apolipoprotein E (ApoE), transthyretin
(TTR),  and  immunoglobulin  kappa
chain C region (IGKC). These proteins
are related to some functional classes
and small molecules. The relations of
binding,  expression,  and  direct
regulation  were  obviously  displayed
among these proteins.
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1644plasma protein with many important functions. It acts as a
carrier protein for vitamin D and its plasma metabolites, and
it also serves as a scavenger protein to clear endotoxins and
extracellular  G-actin  that  are  released  from  necrotic  cells
[35]. DBP has other potential roles, such as responding to
acute  tissue  injury  through  conversion  to  a  macrophage-
activating  factor,  neutrophil  chemotactic  activity,  and
enhancement of C5a-mediated signaling [36]. Geographic,
biologic, and immunologic evidence supports the relationship
between low environmental supplies of vitamin D and an
increased risk of developing multiple sclerosis (MS) [37]. MS
has a typical geographical distribution with a low prevalence
in  equatorial  regions  and  an  increasing  prevalence  with
increasing latitudes in both hemispheres. For example, in the
northern regions of Europe and the USA an increased MS
prevalence is shown in comparison with the southern regions.
Whereas in Australia, an increased prevalence is seen in the
southern coast in comparison with the sub-tropical northern
coast.  Whereas  in  Australia,  there  has  been  an  increased
prevalence  in  the  southern  coast  as  compared  to  the
subtropical  northern  coast.  The  DBP  level  is  reportedly
decreased in the CSF of MS patients [38]. In our current study,
2-DE and western blot analysis revealed significantly reduced
levels of DBP in the CSF samples from the NMO group.
TTR  is  a  beta-sheet  rich  protein  that  is  synthesized
predominantly by parenchymal cells of the liver. It may cleave
the C-terminus of ApoA-I, reducing its capacity to promote
high density lipoprotein (HDL)-mediated cholesterol efflux
and increasing ApoA-I amyloidogenicity [39]. As shown in
Figure 4, TTR, ApoA-I, and HDL strictly interact through
physical  binding.  TTR  is  a  known  negative  acute  phase
protein that is significantly reduced in the CSF of amyotrophic
lateral sclerosis patients [40]. We also found that TTR was
decreased in the CSF of patients with NMO.
Apolipoproteins: ApoA-IV is synthesized primarily in
the intestine and secreted into the plasma. Acute inflammation
can affect plasma ApoA-IV levels [41]. The decreased level
of ApoA-IV in the CSF of NMO patients may reflect the
inflammation status of NMO. Moreover, Langner reported
that ApoA-IV was associated with myelin biosynthesis [42].
ApoE  has  multiple  biologic  properties  aside  from  its
physiologic  role  in  cholesterol  transport.  ApoE  has
immunomodulatory properties both in vitro and in vivo [43].
It directly regulates ApoA-1, HDL, and amyloid precursor
protein  (APP;  Figure  4).  ApoE  is  reported  to  have
neurotrophic activity, and CSF ApoE levels are reduced in
MS, a disease analogous to NMO [44]. Therefore, reduced
levels of ApoE may contribute to the progression of NMO.
Expression proteins related to neurologic disorders: NFs
are  predominantly  localized  in  axons,  and  their  relative
abundance  reflects  the  degree  of  compromised  axonal
function  or  axonal  degeneration  [45].  Miyazawa  and
associates reported finding high concentrations of NF heavy
chains in the CSF of NMO patients [16]. The raised level of
NF suggests its potential value as a marker of axonal damage
and neuronal degeneration in NMO.
Pigment epithelium-derived factor (PEDF), also called
SERPINF1, is a neuroprotective and anti-angiogenic factor
[46] that is widely expressed in the CNS, including the retina,
and  in  most  tissues  of  the  body.  PEDF  is  an  important
neuromodulatory  factor  that  can  provide  effective
neuroprotection  and  a  primary  endogenous  angiogenic
inhibitor in the eye [47]. Trauma or lesion to the optic nerve
may influence the level of PEDF.
Conclusion:  From  our  study,  which  used  proteomic
approaches,  we  have  presented  the  finding  of  proteins
differentially expressed in the CSF of NMO patients. Two
candidate proteins, HP and DBP, whose expression levels
were either elevated or reduced under the NMO pathological
condition,  were  confirmed  by  ELISA  and  western  blot
analysis, respectively. Recognition and characterization of
these proteins and their alterations will likely yield a rich
source of information for describing the disease process and
for helping to reveal predictors of various disease parameters
in NMO. Although some of these proteins are not specifically
affected in different inflammatory neurologic diseases and
may be of limited value as disease-related biomarkers, these
proteins may serve as candidate biomarkers for NMO when
examined in combination. Further steps with a larger group of
patients with NMO, including different subtypes such as optic
neuritis and myelitis, will substantiate these findings.
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1647Appendix 1. Peptide sequence data.
To access the data, click or select the words “Appendix
1.” This will initiate the download of a pdf archive of the file.
Peptide sequence data acquired by MALDI-TOF MS were
searched against the Mascot database to obtain best matches
to known proteins in the SWISS-PROT Database.
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